<\/p>\n
Drug trials fail all the time. What is rare is a failure that costs a company tens of billions of dollars in a single afternoon.<\/p>\n
That is what happened to AstraZeneca (AZN) on July 9. One setback wiped out more market value than the stock had lost on any day in years.<\/p>\n
For investors, the loss was alarming. But the reason behind the loss was even more concerning.\u00a0<\/p>\n
Wall Street had been counting on this drug to become a major seller, and that trial failure took those hopes off the table in one afternoon.<\/p>\n
What AstraZeneca’s trial failure means for the stock<\/p>\n
AstraZeneca shares fell after the company said its experimental heart drug Wainua failed the main goal of a late-stage trial, Reuters reported.\u00a0<\/p>\n
The London-listed stock closed down about 7.7%, its worst single day since March 2020 and the biggest drop on the FTSE 100 on Thursday, July 9.<\/p>\n
More Health Care Stocks:<\/p>\n
BridgeBio stock jumps after rival heart drug fails key trialJPMorgan resets Eli Lilly stock target on drug demandJPMorgan resets UnitedHealth stock target for 2026<\/p>\n
At its lowest point of the day, the drugmaker had shed roughly \u00a319 billion (about $27 billion) in market value, according to Reuters’ report.\u00a0<\/p>\n
The drop stands out because AstraZeneca is usually one of Europe’s steadier large-cap names, not a stock that swings like a small company.<\/p>\n
AstraZeneca shares suffered their worst single day since 2020 after a key heart-drug trial failed.<\/p>\n
Robert Way / Getty Images<\/p>\n
Why the Wainua heart trial disappointed investors<\/p>\n
Wainua, known generically as eplontersen, is a gene-silencing drug that AstraZeneca co-developed with Ionis Pharmaceuticals (IONS), Reuters reports.\u00a0<\/p>\n
The Phase III trial tested it in a heart condition called ATTR-CM, where a faulty protein builds up in the heart and makes it harder to pump blood.<\/p>\n
The study, called CARDIO-TTRansform, did not meet its primary goal.\u00a0<\/p>\n
Adding Wainua to standard care did not significantly cut cardiovascular deaths and repeat heart events over 140 weeks compared with a placebo.<\/p>\n
How the trial design blurred the result<\/p>\n
Analysts pointed to the trial setup. About 57% of the 1,432 patients were already on a stabilizer drug at enrollment, and roughly another quarter added one during the study.<\/p>\n
Because Wainua works by lowering the faulty protein rather than stabilizing it, that overlap made it hard to isolate the drug’s added benefit.\u00a0<\/p>\n
Related: Eli Lilly\u2019s hottest drugs face a quiet new threat<\/p>\n
In patients taking Wainua alone, the company said the result looked better, though that subgroup cannot rescue a missed main goal.<\/p>\n
How rivals and Ionis partners reacted to the news<\/p>\n
The failure did not affect only AstraZeneca. Ionis shares fell about 21%, while companies with approved treatments for the same disease climbed, PharmExec reported.<\/p>\n
BridgeBio (BBIO) and Alnylam Pharmaceuticals (ALNY), which already sell ATTR-CM drugs, rose between 6% and 16% as investors saw a less crowded market ahead.<\/p>\n
The setback reduced prospects for a drug that analysts had estimated could reach about $2 billion in peak annual sales.\u00a0<\/p>\n
The failure removed those expected future sales from valuation models, which is a big part of why the stock fell so hard.<\/p>\n
Why the AstraZeneca selloff was bigger than one drug<\/p>\n
The lost revenue alone does not fully explain a move this size. The deeper issue was confidence.<\/p>\n
BofA analyst Sachin Jain said the miss came as a surprise, noting that he and other investors had not even debated the odds of a primary endpoint failure given the positive earlier data, PharmExec noted.\u00a0<\/p>\n
Jefferies analysts <\/p>\n
called the trial design a possible credibility problem for a management team known for getting trials right.<\/p>\n
For a company that investors treat as a gold standard on trial design, a surprise failure affects trust in future readouts, even ones in unrelated areas.<\/p>\n
What AstraZeneca investors should watch next<\/p>\n
The setback is real, but it does not erase the rest of AstraZeneca’s business. A few things are worth tracking:<\/p>\n
Key signals for AstraZeneca stock from hereFull trial data at the European Society of Cardiology Congress in August, which may show whether the monotherapy signal holds up.The July 27 second-quarter earnings report, and whether management touches full-year guidance.Wainua’s existing approval for a nerve-damage condition in more than 20 countries, which is unaffected by this trial.Broker views on the wider pipeline, with Citi still citing about $46 billion in risk-adjusted peak pipeline sales.<\/p>\n
No single trial defines a company this large, yet a surprise failure is a reminder that even strong drugmakers can fail in drug development.\u00a0<\/p>\n
Anyone weighing the stock should size any position to their own risk tolerance and wait for more data before deciding whether the selloff was an overreaction or a warning.<\/p>\n
Related: Lilly quietly hands Chinese partner its cancer drug<\/p>\n
#AstraZeneca #erases #billions #sobering #reveal<\/p>\n","protected":false},"excerpt":{"rendered":"
Drug trials fail all the time. What is rare is a failure that costs a…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[259],"tags":[16850,5135,16851,5312,12364],"_links":{"self":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/10888"}],"collection":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10888"}],"version-history":[{"count":0,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/10888\/revisions"}],"wp:attachment":[{"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10888"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10888"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10888"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}